Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: KanadaFázis nélkül

One-Time DNA Study for Vasculitis

A legfontosabb adatok

Hol
Hamilton és Toronto (Kanada)Mind a 2 helyszín megnézése

AI-kivonat: kiket keres a vizsgálat

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat az ér-gyulladás (vasculitis) bizonyos típusaiban szenvedő embereket keres. Egyszeri vérmintát adnak egy DNS-vizsgálathoz, amely a betegség kockázatát növelő géneket keresi.

Életkor
7 éves kortól. Az óriássejtes arteritishez a betegség 50 éves kor utáni kezdete kell; a Takayasu-arteritishez 50 éves kor előtti kezdet.
Nem
Bármely nemű személy részt vehet.
A betegség stádiuma
Óriássejtes arteritis, Takayasu-arteritis, polyarteritis nodosa, granulomatosis polyangiitissel (Wegener), mikroszkopikus polyangiitis vagy eozinofil granulomatosis polyangiitissel (Churg-Strauss) diagnózis, a leírásban felsorolt kritériumok szerint.
Biomarker vagy leletérték
A granulomatosis polyangiitissel esetén az egyik kritérium a pozitív ANCA-teszt (PR3- vagy MPO-ANCA). Mindenkinek vállalnia kell a vérvételt a DNS-gyűjtéshez.

A részvétel fő kizáró okai

  • Nem tud beleegyező nyilatkozatot adni és aláírni
  • Már részt vesz a VCRC 5502, 5503, 5504, 5505, 5506, 5522 vagy 5523 protokollban
  • Nem hajlandó vért adni a DNS-gyűjtéshez

Gépi kiolvasás: 2026. november 12.

Helyszínek itt: Kanada

  • St. Joseph's HealthcareHamilton, KanadaContact: Sandra MessierRésztvevőt keres
  • Mount Sinai HospitalToronto, KanadaContact: Nazrana HaqRésztvevőt keres

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

A vizsgálat adatai

Ki végzi
University of Pennsylvania
Azonosító
NCT01241305
A regiszteradat frissítve
2026. január 22.
Eredeti leírás
The purpose of this study is to identify genes that increase the risk of developing vasculitis, a group of severe diseases that feature inflammation of blood vessels. Results of these studies will provide vasculitis researchers with insight into the causes of these diseases and generate new ideas for diagnostic tests and therapies, and will be of great interest to the larger communities of researchers investigating vasculitis and other autoimmune, inflammatory, and vascular diseases.A teljes eredeti leírásKevesebb

VCRC Genetic Repository One-Time DNA Protocol

The purpose of this study is to identify genes that increase the risk of developing vasculitis, a group of severe diseases that feature inflammation of blood vessels. Results of these studies will provide vasculitis researchers with insight into the causes of these diseases and generate new ideas for diagnostic tests and therapies, and will be of great interest to the larger communities of researchers investigating vasculitis and other autoimmune, inflammatory, and vascular diseases.

Bevonási feltételek: Diagnostic criteria for Giant Cell Arteritis Age at disease onset >50 years (required); New onset or new type of localized pain in the head; Temporal artery abnormality (i.e. temporal artery tenderness to palpation or decreased pulsation, unrelated to arteriosclerosis of cervical arteries); ESR of >40mm in the first hour by the Westergren method; Abnormal artery biopsy (i.e. temporal artery biopsy showing vasculitis characterized by a predominance of mononuclear cell infiltration or granulomatous inflammation, usually with multinucleated giant cells); Large Vessel Vasculitis (LVV) by angiogram or biopsy not explained by something else; Diagnostic criteria for Takayasu's Arteritis; Age at disease onset <50 years; Claudication of extremities; Decreased brachial artery pulse (one or both arteries); Blood pressure difference of >10mm Hg between the arms; Bruit over subclavian arteries or aorta; Arteriogram abnormalities compatible with TAK (includes conventional dye angiography or MR angiography or CT angiography); Diagnostic criteria for Polyarteritis Nodosa Major criteria (not explained by other causes) felt by investigator to be due to vasculitis; Arteriographic abnormality; Presence of granulocyte or mixed leukocyte infiltrate in an arterial wall on biopsy; Mononeuropathy or polyneuropathy; Minor criteria (not explained by other causes) felt by investigator to be due to vasculitis; Weight loss > 4 kg; Livedo reticularis, cutaneous ulcerations, or skin nodules; Testicular pain or tenderness; Myalgias; Diastolic blood pressure > 90 mm Hg; Elevated BUN or serum creatinine levels; Ischemic abdominal pain; Isolated cutaneous Polyarteritis Nodosa 1. Biopsy-proven cutaneous PAN; Diagnostic criteria for Granulomatosis with Polyangiitis (Wegener's) (GPA) and Microscopic Polyangitis (MPA); Diagnosis of GPA or MPA. Widely accepted diagnostic criteria, as opposed to classification criteria or definitions, have not been developed for GPA \& MPA; For diagnosis of GPA meets at least 2 of the following 5 modified ACR criteria:; Nasal or oral inflammation with oral ulcers or nasal discharge with pus or blood; Abnormal chest radiograph with nodules, fixed infiltrates, or cavities; Urinary sediment with microhematuria or red cell casts; Granulomatous inflammation within the wall of an artery or in the perivascular area on biopsy; Antineutrophil cytoplasmic antibody (ANCA) positive by enzyme immunoassay for either PR3- or MPO-ANCA; For diagnosis of MPA, meets the Chapel Hill Consensus Conference Definition for MPA:; Necrotizing vasculitis, with few or no immune deposits, that affects small vessels (i.e., capillaries, venules, arterioles); Necrotizing arteritis involving small- and medium-sized arteries may be present; Necrotizing glomerulonephritis is very common; Pulmonary capillaritis often occurs; Diagnostic criteria for Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss); Asthma; Peak peripheral blood eosinophilia of >10% of total WBC; Peripheral neuropathy attributable to vasculitis; Transient pulmonary infiltrates on chest imaging studies; Paranasal sinus abnormalities or nasal polyposis; Eosinophilic inflammation on tissue biopsy; If patients have 4 of the above 6 criteria but lack clearcut documentation of small vessel vasculitis, they are also eligible for enrollment; General Exclusion Criteria:; Inability to give informed consent and to sign the consent form; Enrolled in VCRC protocols 5502, 5503, 5504, 5505, 5506, 5522, or 5523; Unwilling to provide blood for DNA collection.

ClinicalTrials.gov NCT01241305